Cell & Gene Therapy Insights feature: “Thinking ahead: developing biosynthetic blood to anticipate donor drought”

Co-Written by Andrew Spencer Goldman, RSV General Counsel and Head of Policy, Taylor Rose, RSV Global Access Fellow, and Luna Patel, RSV Volunteer.

https://insights.bio/cell-and-gene-therapy-insights/journal/article/2694/Thinking-ahead-developing-biosynthetic-blood-to-anticipate-donor-drought?showmodal

How could viable biosynthetic blood technology radically transform the health outcomes of people around the world? How is biosynthetic blood different and a more promising option for patients than artificial blood? What investments are needed to push development to ensure sustainable, commercially viable, and equitable global access? 

This week Cell & Gene Therapy Insights published, "Thinking ahead: developing biosynthetic blood to anticipate donor drought," co-written last fall by Andrew Spencer Goldman, Roivant Social Ventures (RSV) General Counsel and Head of Policy, and Taylor Rose, RSV Global Access Fellow.

"There is a tremendous global need to develop a sufficient, sustainable, and safe blood supply for a wide variety of medical needs...

Unfortunately, the 118.5 million pints of blood donated annually, with the inherent challenges of maintaining a secure blood supply, are insufficient to meet global need, particularly in low- and middle-income countries... 

Fortunately, promising scientific research has shown success creating red blood cells (RBC) from human stem cells that mimic human donor blood, suggesting that there is a real possibility to develop an unlimited biosynthetic blood supply through creation of these biosynthetic RBCs..."

Read the full publication by clicking here.

This piece was also co-written by Shane Kilpatrick, Marinna Madrid, Zhong Ri Lim, Steve Oh, Lena Patel, and Barbara A Nelsen. 

Next
Next

Los Angeles Times feature: “Why the lack of diversity in drug industry leadership is hurting women and people of color,” written by Lindsay Androski, RSV CEO